Dana-Farber/Mass General Brigham Cancer Care, Inc.

Boston, Massachusetts 02215

2 studies enrolling now · 6 studies all time

What they study most

Acute Myeloid Leukemia, Advanced Renal Cell Carcinoma, Advanced or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell, Carcinoma, Renal Cell Metastasis, Carcinoma, Renal Cell, Advanced, Clear Cell Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma, Hematologic Neoplasms, Metastatic Renal Cell Cancer, Metastatic Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma ( mRCC)

Studies at this site

• A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies — Recruiting now
• Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer — Recruiting now
• A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma — Running, not enrolling
• A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma — Running, not enrolling
• Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL — Stopped early
• Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation — Completed